IGC Pharma, Inc. (IGC)
(Real Time Quote from BATS)
$0.36 USD
0.00 (-0.55%)
Updated Oct 4, 2024 03:08 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for IGC Pharma, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 1 | 1 | 0 | 1 | 4 |
Cost Of Goods | 1 | 0 | 0 | 1 | 4 |
Gross Profit | 1 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 11 | 12 | 16 | 9 | 7 |
Income After Depreciation & Amortization | -10 | -12 | -15 | -9 | -7 |
Non-Operating Income | -3 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -13 | -12 | -15 | -9 | -7 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -13 | -12 | -15 | -9 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -13 | -12 | -15 | -9 | -7 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -9 | -11 | -15 | -8 | -7 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -10 | -12 | -15 | -9 | -7 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 58.84 | 52.58 | 49.99 | 41.96 | 39.49 |
Diluted EPS Before Non-Recurring Items | -0.22 | -0.22 | -0.19 | -0.21 | -0.17 |
Diluted Net EPS (GAAP) | -0.22 | -0.22 | -0.30 | -0.21 | -0.19 |
Fiscal Year end for IGC Pharma, Inc falls in the month of March .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.27 | 0.30 | 0.20 | 0.29 | 0.56 |
Cost Of Goods | 0.11 | 0.12 | 0.07 | 0.12 | 0.30 |
Gross Profit | 0.16 | 0.17 | 0.13 | 0.17 | 0.26 |
SG&A, R&D, and Dept/Amort Expenses | 2.56 | 2.34 | 3.13 | 2.67 | 2.40 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.40 | -2.17 | -3.00 | -2.50 | -2.14 |
Non-Operating Income | 0.02 | -0.72 | -2.59 | 0.04 | 0.06 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.38 | -2.89 | -5.59 | -2.45 | -2.08 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.38 | -2.89 | -5.59 | -2.45 | -2.08 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.38 | -2.89 | -5.59 | -2.45 | -2.08 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 72.81 | 72.13 | 63.73 | 54.30 | 53.08 |
Diluted EPS Before Non-Recurring Items | -0.03 | -0.04 | -0.09 | -0.05 | -0.04 |
Diluted Net EPS (GAAP) | -0.03 | -0.04 | -0.09 | -0.05 | -0.04 |